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The difficult patient: drug 
interaction and the influence of 
concomitant diseases on the 
treatment of hypothyroidism
O paciente difícil: interação entre drogas e influência de 
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Thyroid hormone therapy is often rewarding, simple and inexpensive. Most patients are satisfied with 
one single tablet of synthetically derived levothyroxine 
daily. Once the dosage has been adjusted to give opti-
mal clinical response and normal serum TSH, the repla-
cement dosage often remains stable for years. However, 
nearly 10% of the patients are not satisfied and another 
important part of our patients is not well controlled and 
needs unusually high doses of thyroid hormone replace-
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The difficult hypothyroid patient
A series of recent publications have been pointing to 
genetic polymorphisms in deiodinases and thyroid hor-
mone transporters as the main causes of dissatisfaction. 
Common germline genetic variations are probably re-
sponsible for the relatively wide range of serum thyroid 
hormone levels observed in the normal population and 
may also be involved in the differential bioavailability 
of thyroid hormones in different tissues (2). However, 
this review does not focus on the dissatisfied patient, 
but on the patient who is difficult to control.
compliance wiTh TheRapy anD meDicaTion-
TaKing behavioR 
The causes for frequent-dose adjustment or high-
dose requirement are, in general, prosaic. The most 
common cause is poor compliance with therapy and 
medication-taking behavior. This issue is relevant for 
the management of all chronic asymptomatic or oli-
gosymptomatic diseases, such as diabetes, hyperten-
sion and other diseases in which no immediate physical 
symptoms result from such behavior (3). One day’s 
tablet represents 24% of the weekly dose and, be-
cause of the long half-life of thyroxine, the influence 
of missing a day on thyroid hormones and TSH lev-
els will manifest over several days. A recent publica-
tion involving a large number of Canadian elders who 
had received a new prescription for an antihypertensive 
agent demonstrated that persistence at 1 year dropped 
50-60% (4). The authors found that compliance was 
greater in women, patients of higher socioeconomic 
status, and younger individuals, with lower burdens of 
comorbidities (4). Unfortunately, most of our patients 
do not fulfill this profile.
Confirming other data on the subject, we published 
a compliance study comprising 100 patients from pub-
lic hospitals in Campinas and Rio de Janeiro, who pre-
sented persistently elevated TSH levels despite increas-
ing the levothyroxine dose (5). Our poor compliance 
rate was similar to that seen in literature: 82% of the 
patients. Sixty two percent of the patients had a poor 
medication-taking behavior mostly because they for-
got or neglected to take their pills, but 12% of these 
patients complained about intolerance or side effects 
and 8% claimed they could not afford to buy the medi-
cation (5). Levothyroxine is allegedly supplied at our 
primary care institutions, but unfortunately this sup-
ply is not regular. Subsequently, we supplied one of the 
four preparations containing levothyroxine commer-
cially available at that time, reinforced the importance 
of the medication by giving lectures to the patients, and 
undertook a simple pill counting control compliance 
measure. All patients were controlled after one month 
with all four preparations; however, the most impor-
tant finding of our trial was that 18% of these patients, 
after just one month of adequate medication-taking, 
were hyperthyroid. Indicating they had already been 
prescribed a levothyroxine dosage higher than they 
were really in need of. And, certainly, the fact that they 
became hyperthyroid when they started to take their 
pills appropriately represents a risk. None of our pa-
tients had any cardiac symptom or complained of any 
problem, but they could have had serious problems es-
pecially considering that most of these patients were 
elderly and presented comorbidities. 
Excluding poor medication-taking behavior is usu-
ally a difficult task. After exhausting every usual mea-
sure for compliance such as pill counting, counseling 
methods, motivational interviewing and problem solv-
ing treatment, a clinical test to estimate levothyrox-
ine absorption may be proposed. The test consists of 
a single large dose of thyroxine administration, usually 
1,000 mcg, and then monitoring serum T4 levels over 
time (6). Unfortunately, there are no well-established 
standards for this test. Even though it indicates that the 
patient absorbs thyroxine when exposed to a large dose, 
it does not rule out impairment of normal dose absorp-
tion. Moreover, the test does not quantify the absorp-
tion impairment caused by the edema produced by the 
hypothyroidism on the small bowel mucosa. Hence, 
simply increasing the levothyroxine dose may have the 
same practical effect of submitting the patient to the 
single dose test, with the advantage of treating him.
aDequacy of meDicaTion 
Once poor-medication is discarded and before con-
sidering drug interaction and concomitant diseases, it 
is necessary to check if the patient medication is ad-
equate. It is important to remember that certain con-
ditions may physiologically require higher doses of 
thyroid hormone replacement, such as pregnancy or 
childhood (Table 1). 
Obesity may also be a cause of a higher levothyro-
xine requirement. In fact, individual levothyroxine re-
quirements are more related to the lean body mass than 
to the total body weight (7). On studying more than 
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The difficult hypothyroid patient
re is considerable concern on the bioequivalence stan-
dards for levothyroxine product comparisons (9) and 
the American Thyroid Association (ATA), along with 
the American Association of Clinical Endocrinologists 
(AACE), and The Endocrine Society (TES) have en-
dorsed a joint statement expressing concern about the 
flawed methodology used to determine bioequivalence 
and the potential harm it could bring to patients (16). 
In fact, there have been a series of adverse event reports 
(17). Patients should be alerted that they will be requi-
red to perform additional blood tests and dose adjust-
ments after switching preparations.
DRug inTeRacTion anD concomiTanT 
Diseases 
If the patient was correctly diagnosed, poor medica-
tion-taking or compliance issues were discarded, and 
the dose prescribed is adequate, you may be facing a 
drug interaction problem or a concomitant disease that 
impairs levothyroxine’s proper absorption or action 
(Table 2). 
Table 2. Causes of impaired levothyroxine absorption
Drugs
Proton-pump inhibitors (PPI) Calcium salts
Aluminium, magnesium hydroxide Calcium carbonate
Sucralfate Orlistat
Ion exchange resins Cation exchange resins
Ferrous sulfate Bile acid sequestrants 
(Cholestyramine; Colestipol)
Diseases
Helicobacter pylori infection Celiac disease
Atrophic gastritis Short bowel syndrome
Giardiasis and other parasitic diseases Lactose intolerance





The absorption of levothyroxine occurs within an 
interval of 3 hrs of ingestion, mainly in the jejunum and 
ileum (18-20). On average, approximately 70%-80% of 
the available tablet dose is absorbed by the euthyroid 
individual, and this absorption rate may diminish in the 
hypothyroid patient (18). Absorption is maximal when 
the stomach is empty, reflecting the importance of gas-
tric acidity in the process (21,22). In fact, the comple-
Table 1. Causes of high-dose thyroid hormone replacement
Poor medication-taking behavior/compliance
Adequacy of medication: pregnancy, infancy/adolescence, obesity
Drug interaction
Concomitant diseases
Type 2 deiodinase polymorphisms/ thyroid hormone transporters
thyroid disease, Asvold and cols. (8) proved that low 
thyroid function was associated with high body mass for 
men and women (8). Two hypotheses have been pro-
posed to explain the relation of thyroid function with 
body mass. The first one involves the effect of leptin 
and other adipokines (9), which is favored by the follo-
wing facts: weight reduction in obese individuals may 
be associated with reduced thyroid function (10,11), 
and patients with anorexia nervosa who gain weight 
have increased thyroid function (12). The second hy-
pothesis suggests that low thyroid function may lead to 
obesity, probably reducing basal metabolic rate (13).
Requirement also seems to be associated with hor-
monal status. Studying 50 patients after thyroidectomy, 
Jackeline Jonklaas (14) found that the weight-based 
levothyroxine dosage required to normalize TSH was 
1.7 mcg/kg in both sexes; however, premenopausal 
women appeared to have a greater dosage requirement 
than both postmenopausal women and men (14). Of 
course, dose requirements are also age-dependent, pos-
sibly because of the combination of weight loss, lean 
mass loss and decreased clearance of T4 (14,15).
Another very common problem is that the patient 
may be using an inadequate preparation or a prepara-
tion with no bioequivalence. Levothyroxine is a narrow 
therapeutic range drug for which precise and consis-
tent dosing are essential, particularly in the elderly and 
in high-risk thyroid cancer patient treatment. It is not 
unusual to see patients using “natural medicines” that 
do not contain appropriate doses of the active princi-
pals, formulas or manipulated preparations that lack a 
proper control. There are different brand-name and 
generic levothyroxine products being manufactured in 
Brazil and many patients switch from one to another 
at their convenience or at the pharmacist’s or relatives’ 
advice, frequently without the prescribing physician’s 
knowledge. Generic levothyroxine is considered equi-
valent to the brand names and, because there is a cost 
differential between generic levothyroxine and many of 
the brand name products, physicians and patients have 
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xity of the acid producing machinery in the stomach 
may contribute to the individual variability observed in 
daily thyroxine requirement in a longitudinal evalua-
tion (23).
There is an increase in the requirement of oral 
thyroxine in all conditions characterized by impaired 
gastric acid secretion, which is more pronounced in 
adult patients presenting with atrophic gastritis and 
concomitant H. pylori infection, who have severe hy-
pochlorhydria (24). In an attempt to reduce the size 
of their goiters or at least to minimize further growth, 
Centanni and cols. (21) treated 248 multinodular goi-
ter patients with levothyroxine (21). The dose was pro-
gressively increased until a low serum thyrotropin level 
(0.05 to 0.20 mU per liter) was reached. There were 
113 patients with multinodular goiter and impaired 
gastric acid secretion. Fifty-three had H. pylori-related 
nonatrophic gastritis and 60 patients had atrophic gas-
tritis. The authors observed that patients with atrophic 
gastritis required an increase of 27% in the thyroxine 
dose, whereas patients with H. Pylori non-atrophic gas-
tritis required an increase of 22% in their dose. Interes-
tingly, there was an additive effect: patients with both 
H. pylori and atrophic gastritis needed a 34% higher 
dose of T4. Although the clinical importance of the-
se findings is fairly clear, the mechanism by which in-
testinal absorption of thyroxine is impaired in patients 
with hypochlorhydria is unknown. We may only specu-
late that oral thyroxine is administered as sodium salt, 
which is less lipophilic than the native hormone, which 
enters target cells both through passive diffusion and 
in a carrier-mediated, inhibitable way (25,26). In this 
respect, achlorhydria due to atrophic gastritis (27,28) 
and ammonia production, or both, which are characte-
ristic of H. pylori infection (29,30) may alter the ioniza-
tion status and the conformational characteristics of the 
thyroxine molecule and thus, the efficiency of intestinal 
absorption of the hormone.
It is important to remember that atrophic gastritis 
and serum parietal-cell antibodies are associated with 
Hashimoto’s disease and serum thyroid peroxidase an-
tibodies. Therefore, patients with Hashimoto’s disease 
are more susceptible to present a concomitant autoim-
mune atrophic gastritis. And, of course, many indivi-
duals with atrophic gastritis and parietal-cell antibodies 
also present H. pylori infection (21). 
Among the 248 multinodular goiter patients trea-
ted with thyroxine by Centanni and cols. (21), there 
were 11 patients diagnosed with H. pylori who were 
treated for this infection. TSH levels measured befo-
re and after H. pylori eradication demonstrated a clear 
effect of gastric infection on the absorption of thyroxi-
ne impairment, an effect that has been proved by others 
too (21,31). In H. pylori infection, bacterial production 
of urease neutralizes gastric pH, impairing the absorp-
tion of many drugs (31). Other 10 patients with mul-
tinodular goiter and gastroesophageal reflux disease, 
who were treated with both thyroxine and omeprazo-
le, had their serum thyrotropin levels evaluated before 
and after treatment. Omeprazole has also got an im-
portant effect per se, probably because it causes hypo-
chlorhydria, likewise all proton-pump inhibitors (PPI) 
do (21,32). In conclusion, H. pylori infection and hy-
pochlorhydria should be considered when prescribing 
any drugs for which absorption is potentially affected 
by intragastric pH. 
In addition to PPI, antacids also impair levothyro-
xine absorption. There are other commonly used drugs 
that impair intestinal absorption such as ion exchange 
resins, bile acid sequestrants, and sucralfate, which have 
the same effect. Ferrous sulfate, frequently used to treat 
anemia, may impair thyroxine as well as orlistat absorp-
tion, a drug that works by interfering with the action of 
gastrointestinal (GI) lipase in the GI tract, and calcium 
(33). There is an increasing number of drugs that have 
been reported to affect levothyroxine absorption (33) 
(Table 2). 
Furthermore, a series of other diseases can im-
pair levothyroxine absorption as well. Celiac disease is 
worth the mention. In fact, likewise atrophic body gas-
tritis, celiac disease and other autoimmune conditions, 
including inflammatory small bowel disease, are fre-
quently associated with autoimmune thyroiditis (34,35), 
which in turn consists in the main cause of hypothyroi-
dism in adult patients (36). Celiac disease may have mild 
or subtle symptoms, and there is a case report in which 
resistant hypothyroidism appeared to be the only major 
manifestation of the disease (37). The patient improved 
after a gluten-free diet was introduced (37).
Bariatric surgery and all surgeries that reduce gas-
trointestinal absorption surface may also impair thyro-
xine absorption (38). It is especially relevant to remem-
ber that certain parasitic diseases may be an important 
cause of malabsorption in underdeveloped countries. 
There is a report of a severe case of hypothyroidism 
reputed to have been caused by an intestinal giardiasis 
(39). Other causes of malabsorption may include lacto-
se intolerance (40).
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Cardiovascular diseases deserve a special considera-
tion concerning thyroid hormone administration. We all 
fear the potential detrimental effects of thyroid hormo-
ne administration in a variety of clinical settings. Indeed, 
high doses of thyroxine can cause cardiac ischemia, even 
in the absence of significant coronary artery disease; 
increase oxygen demand, coronary spasm and arrhyth-
mias (41). For this reason, levothyroxine is introduced 
in very small doses, in general, half of the 25 mcg tablet 
in patients with cardiovascular diseases. Increases in do-
sage are also made very cautiously and slowly and, many 
times, we are tempted to maintain the patient in a state 
of subclinical hypothyroidism. However, experimental 
data suggest that thyroid hormones improve myocar-
dial functions, increase capillary flow and induce an-
giogenesis after myocardial infarction (42-48). In fact, 
thyroid hormone administration shows inotropic and 
antiarrhythmic properties and reduces the risk of death 
after and some clinical conditions such as chronic con-
gestive heart failure (42), organ transplantation (43,44), 
coronary artery (45) and cardiopulmonary bypass (46), 
myocardial ischemia (47) and in prolonged critical ill-
ness (48). Consequently, it is important to always aim 
at a target TSH in the normal range for the patient’s 
age, especially if the patient has a cardiovascular disease. 
Also, it is important to remember that congestive heart 
failure is associated to altered morphology, permeability, 
and absorption of the digestive tract (49).
nuTRiTional habiTs
Nutritional habits are also very important to control 
hypothyroid patients (Table 2). Most of the active 
components of a thyroxine pill are absorbed within the 
first 20-30 minutes after ingestion, although comple-
tion of absorption takes three hours. Therefore, it is 
recommended to obey a 30-minute interval between 
thyroxine pill ingestion and breakfast. A series of re-
ports have demonstrated that coffee, especially espres-
so coffee, impairs thyroxine absorption (50). Dietary 
fibers appear to have a smaller, but still significant effect 
on thyroxine absorption (51). Grapefruit juice and pro-
bably other citric fruits might also impair thyroxine ab-
sorption (52).
oTheR DRugs ThaT inTeRacT wiTh ThyRoxine 
In addition to drugs that cause impairment in thyroxi-
ne absorption, there are other drugs that interact with 
thyroxine. Although they are not the scope of this re-
view, it is worth mentioning that there are drugs that 
may increase hepatic metabolism and cause hypothyroi-
dism (carbamazepine, hydantoins, phenobarbital, ri-
fampin); that may cause a decrease in thyroid hormone 
secretion and, therefore, cause a higher dose require-
ment of thyroxine (aminoglutethimide, amiodarone, 
iodide-including and iodine-containing radiographic 
contrast agents, lithium, methimazole, propylthioura-
cil, sulfonamides, tolbutamide); that may decrease T4 
5’-deiodinase activity (amiodarone, beta-adrenergic 
antagonists: propranolol > 160 mg/day, glucocorti-
coids: dexamethasone ≥ 4 mg/day, propylthiouracil); 
that may increase serum TBG concentration (estro-
gen, clofibrate, heroin/methadone, mitotane, tamo-
xifen); that may decrease serum TBG concentration 
(androgens/anabolic steroids, glucocorticoids, nicoti-
nic acid, asparginase); that may cause protein-binding 
site displacement (furosemide: > 80 mg IV, heparin, 
hydantoins, nonsteroidal anti-inflammatory drugs: 
fenamates, phenylbutazone, salicylates > 2 g/day). 
A series of other drugs need attention because, throu-
gh unknown or complex mechanisms, they may inter-
fere with thyroxine therapy; antidiabetic agents: bigua-
nides, meglitinides, sulfonylureas, thiazolidinediones, 
insulin; antidepressants: tricyclic (e.g., amitriptyline), 
tetracyclics (e.g., maprotiline), selective serotonin 
reuptake inhibitors (SSRIs; e.g., sertraline); growth 
hormones: somatrem, somatropin; oral anticoagulants: 
coumarin derivatives, indandione derivatives; cytoki-
nes: interferon-α, interleukin-2; others: ketamine, 
sympathomimetics, cardiac glycosides, chloral hydrate, 
diazepam, ethionamide, lovastatin, metoclopramide,6-
mercaptopurine, nitroprusside, para-aminosalicylate 
sodium, perphenazine, resorcinol (excessive topical 
use), thiazide diuretics.
Interestingly, some agents, such as amiodarone and 
iodide may cause both hypo- and hyperthyroidism 
(53,54). Amiodarone is a drug very frequently used in 
Brazil. We have a 10-million Chagas disease population 
and amiodarone is a very potent and effective antiar-
rhythmic drug. It is a benzofuran-derived, iodine-rich 
compound with some structural similarity to thyroxine 
(T4). Amiodarone contains approximately 37% iodine 
by weight. Each 200-mg tablet is estimated to contain 
approximately 75 mg of organic iodide, 8%-17% of 
which is released as free iodide. Standard maintenan-
ce therapy with 200 mg amiodarone can provide more 
than 100 times the daily iodine requirement. Amioda-
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rone causes a wide spectrum of effects on the thyroid 
(53,54). In a study of 81 Chagas disease patients using 
amiodarone, we found that 21% of the patients had ele-
vated TSH levels and 8% low TSH levels (55). Amioda-
rone may also decrease T4 deiodinase activity. Likewise 
propanolol, dexametasone and PTU may decrease T3 
levels. Although usually normal, serum T4 levels may 
occasionally be slightly increased. In patients treated 
with large doses of propranolol (> 160 mg/day), T3 
and T4 levels change slightly, TSH levels remain nor-
mal, and patients are clinically euthyroid. It should be 
noted that actions of particular beta-adrenergic antago-
nists may be impaired when the hypothyroid patient is 
converted to the euthyroid state. Short-term adminis-
tration of large doses of glucocorticoids may decrease 
serum T3 concentrations by 30%, with minimal change 
in serum T4 levels. However, long-term glucocorticoid 
therapy may result in slightly decreased T3 and T4 le-
vels due to decreased TBG production. 
Since many of our hypothyroid patients are also dia-
betic, we should remember the TSH-lowering effect of 
metformin (56).
Finally, we need to mention the effects of a growing 
list of thyroid disruptors that may also affect thyroid 
hormone metabolism at many levels (57) (Table 3).
An increasing amount of toxic substances has been 
described, many of which we still do not fully unders-
tand how they affect thyroid hormones. For instance, 
a study of 42 healthy non-smoker petrol filling workers 
from India found a significant toxic effect on workers 
exposed for longer duration who presented lower 
TSH levels. However, whereas their serum T3 levels 
dropped, T4 and free T4 levels augmented (58). The 
effects of thyroid disruptors are complex and still di-
fficult to interpret. They may account for a part of the 
patients who we are convinced that are compliant, ade-
quately medicated and do not present any absorption 
impairment, but have a hard time controlling their hy-
pothyroidism. 
In conclusion, the patient difficult to control most 
frequently is not compliant or was not adequately diag-
nosed/prescribed. Indeed, the majority of our patients 
fit this profile and become adherent to therapy after 
a few good conversations. In some patients, however, 
we need to exclude concomitant disease and drug inte-
raction. Eventually, in the rare cases in which all these 
issues were discarded, we remain with the hypothesis 
of the presence of thyroid disruptors, deiodinase or 
thyroid hormone transporter polymorphisms leading 
to higher dose requirements and we just adjust thyroxi-
ne dose. Treating the hypothyroid difficult patient may 
not be so difficult, after all.
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
Table 3. Thyroid disruptors: clinical effect and putative mechanism. Notice that some products have several toxic effects
xenobiotic product clinical effect on thyroid metabolism putative mechanism
Perchlorates, thiyocyanate, nitrate, phthalates, bromates Decreases synthesis of T3 and T4 Blocking iodide uptake into thyroid cell
Soy, isoflavones, methimazole, benzophenone 2 
(pesticide), amitrole (pesticide)
Decreases synthesis of T3 and T4 Blocking TPO production into thyroid cell
PCBs, pentachlorophenol, flame retardants, phthalates Possible effect on fetal brain T4 production and brain 
development
Compete to thyroid transport protein
Dioxin, PBDE, chlordane (pesticide) Increase billiary elimination of both T4 and T3 Alter transport across cell membrane
Acetochlor (herbicide) Increase billiary metabolism of both T4 and T3 Enhance hepatic metabolism
Triclosan, PCBs, dioxin, difuran, pentachlorophenol 
(pesticide)
Decrease sulfation of thyroid hormones and possibly 
decrease peripheral T3 synthesis
Inhibit sulfation
PCBs, octyl methoxycinnamate, FD&C red dye Decrease peripheral T3 synthesis Inhibit deiodinase activity
DDT, PCBs Decrease T3 and T4 production Inhibit TSH receptor
Polychlorinated biphenyls (PCBs) were commonly used as stabilizing additives in the manufacture of flexible PVC coatings for electrical wiring and electronic components to enhance the heat and fire 
resistance of the PVC. 
Perchlorates are used extensively within the pyrotechnics industry, and ammonium perchlorate is also a component of solid rocket fuel.
Thiyocyanate is used as a precursor for the synthesis of pharmaceuticals and other specialty chemicals.
Dioxins are the by-products of various industrial processes (i.e., bleaching paper pulp, and chemical and pesticide manufacture) and combustion activities (i.e., burning household trash, forest fires, 
and waste incineration).
Bromates are formed many different ways in municipal drinking water.
Phthalates are mainly used as plasticizers (substances added to plastics to increase their flexibility, transparency, durability, and longevity).
Difuran is used in the elaboration and/or manufacturing of flavor and fragrance agents.
Octyl methoxycinnamate is an component used in some sunscreens and lip balms.
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